Lead Product Candidate for Refractive Indications APX3330
Our second product candidate, APX3330, is a twice-a-day oral tablet designed to target multiple pathways relevant to retinal and choroidal vascular diseases such as DR and DME. Prior to our in-licensing of the product candidate, APX3330 had been studied in six Phase 1 and five Phase 2 clinical trials totaling over 440 patients, for inflammatory and oncology indications, and had demonstrated promising evidence of target engagement, tolerability, pharmacokinetics, and durability.
In the first quarter of 2021, we initiated ZETA-1, a Phase 2 trial investigating APX3330 for the treatment of moderately severe non-proliferative DR (NPDR) and mild proliferative DR (PDR), as well as patients with DME without loss of central vision. We anticipate advancing APX3330 towards an NDA in the future.